The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease
Abstract
The clinical features of relapses and progression largely define multiple sclerosis phenotypes. A relapsing course is followed by chronic progression in some 80% of cases within 2 decades. The relationship between these phases and long-term outcome remains uncertain. We have analysed these clinical features within a well-studied natural history cohort with mean follow-up of 25 years. For the entire cohort, median times to reach Disability Status Scale (DSS) 6, 8 and 10 were 12.7, 20.6 and 43.9 years, respectively. Among 824 attack-onset patients, the great majority entered a progressive phase with a mean time to progression of 10.4 years. The effects of relapses often cloud the clinical onset of progression. However, there are circumstances where onset of progression is early, relatively discrete and identifiable at DSS of 2 or less. Three subgroups allow for clarity of outcome comparison and they are (i) cases of primary progressive (PP) disease, (ii) attack-onset disease where only a single attack has occurred before onset of progression (SAP) and (iii) secondary progressive (SP) disease where recovery from relapses allows recognition of the earliest clinical stages when progression begins. Here we compare survival curves in these three groups. Among cohorts of SAP (n = 140), PP (n = 219) and SP (n = 146) where progression was stratified by DSS at its onset, there was no difference in time to DSS 6, 8 and 10. These findings demonstrate that the progressive course is independent of relapses either preceding the onset of relapse-free progression or subsequent to it. Among SAP patients, the degree of recovery from the single defining exacerbation had no significant effect on outcome. The site of the original attack was not usually where progression began. The relatively stereotyped nature of the progressive phase seen in all progressive phenotypes suggests regional and/or functional differential susceptibility to a process that appears degenerative in nature. The highly prevalent distal corticospinal tract dysfunction in progressive disease and the pathologically demonstrated selective axonal loss seen in this tract raises the possibility of a dying back central axonopathy, at least in part independent of plaque location or burden. Despite considerable individual variation, the progressive course of disability seen in groups of PP, SAP and SP-DSS2 is similarly stereotyped in quality and pace and may entail mechanisms common to all forms of progressive multiple sclerosis. The possibility that this is the primary process in some cases must be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Self-citationAxonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
The IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.655 · Cited by 2,085
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,073
Self-citationJohnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,898
The clinical course of neuromyelitis optica (Devic’s syndrome)
Wingerchuk, D. M., Hogancamp, W. F., O’Brien, P. C., & Weinshenker, B. G. (1999) · Neurology · doi:10.1212/wnl.53.5.1107 · Cited by 1,822
Self-citationAxonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532
Cited by
Compston, A., & Coles, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61620-7 · Cited by 4,372
Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724
Fisniku, L. K., Brex, P. A., Altmann, D. R., Miszkiel, K. A., Benton, C. E., Lanyon, R., Thompson, A. J., & Miller, D. H. (2008) · Brain · doi:10.1093/brain/awm329 · Cited by 897
Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
Howell, O. W., Reeves, C. A., Nicholas, R., Carassiti, D., Radotra, B., Gentleman, S. M., Serafini, B., Aloisi, F., Roncaroli, F., Magliozzi, R., et al. (2011) · Brain · doi:10.1093/brain/awr182 · Cited by 858
Primary-progressive multiple sclerosis
Miller, D. H., & Leary, S. M. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70243-0 · Cited by 818
Scalfari, A., Neuhaus, A., Degenhardt, A., Rice, G. P., Muraro, P. A., Daumer, M., & Ebers, G. C. (2010) · Brain · doi:10.1093/brain/awq118 · Cited by 711
Self-citationEnvironmental factors and multiple sclerosis
Ebers, G. C. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70042-5 · Cited by 629
Self-citationMultiple sclerosis: clinical aspects
Oh, J., Vidal-Jordana, A., & Montalban, X. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000622 · Cited by 620
Evidence for a two-stage disability progression in multiple sclerosis
Leray, E., Yaouanq, J., Le Page, E., Coustans, M., Laplaud, D., Oger, J., & Edan, G. (2010) · Brain · doi:10.1093/brain/awq076 · Cited by 596
Progressive multiple sclerosis: from pathogenic mechanisms to treatment
Correale, J., Gaitán, M. I., Ysrraelit, M. C., & Fiol, M. P. (2016) · Brain · doi:10.1093/brain/aww258 · Cited by 573
The epidemiology of multiple sclerosis
(2016) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-802973-2.00011-2 · Cited by 514
Epidemiology of multiple sclerosis
Leray, E., Moreau, T., Fromont, A., & Edan, G. (2016) · Revue Neurologique · doi:10.1016/j.neurol.2015.10.006 · Cited by 478
Will the real multiple sclerosis please stand up?
Stys, P. K., Zamponi, G. W., van Minnen, J., & Geurts, J. J. G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3275 · Cited by 475
Clinical Course of Multiple Sclerosis
Klineova, S., & Lublin, F. D. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a028928 · Cited by 401
Revised diagnostic criteria of multiple sclerosis
Milo, R., & Miller, A. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.012 · Cited by 326
A secondary progressive clinical course is uncommon in neuromyelitis optica
Wingerchuk, D. M., Pittock, S. J., Lucchinetti, C. F., Lennon, V. A., & Weinshenker, B. G. (2007) · Neurology · doi:10.1212/01.wnl.0000254502.87233.9a · Cited by 326
Self-citationOnset of secondary progressive phase and long-term evolution of multiple sclerosis
Scalfari, A., Neuhaus, A., Daumer, M., Muraro, P. A., & Ebers, G. C. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304333 · Cited by 291
Self-citationAge and disability accumulation in multiple sclerosis
Scalfari, A., Neuhaus, A., Daumer, M., Ebers, G. C., & Muraro, P. A. (2011) · Neurology · doi:10.1212/wnl.0b013e318230a17d · Cited by 279
Self-citationNew natural history of interferon‐β–treated relapsing multiple sclerosis
Trojano, M., Pellegrini, F., Fuiani, A., Paolicelli, D., Zipoli, V., Zimatore, G. B., Di Monte, E., Portaccio, E., Lepore, V., Livrea, P., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21102 · Cited by 270
Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis
Tutuncu, M., Tang, J., Zeid, N. A., Kale, N., Crusan, D. J., Atkinson, E. J., Siva, A., Pittock, S. J., Pirko, I., Keegan, B. M., et al. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458512451510 · Cited by 267
New perspectives in the natural history of multiple sclerosis
Tremlett, H., Zhao, Y., Rieckmann, P., & Hutchinson, M. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e3973f · Cited by 261
Spinal cord MRI in multiple sclerosis—diagnostic, prognostic and clinical value
Kearney, H., Miller, D. H., & Ciccarelli, O. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.80 · Cited by 235
Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome
Kantarci, O. H., Lebrun, C., Siva, A., Keegan, M. B., Azevedo, C. J., Inglese, M., Tintoré, M., Newton, B. D., Durand‐Dubief, F., Amato, M. P., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24564 · Cited by 167
Late motor decline after accomplished remyelination: Impact for progressive multiple sclerosis
Manrique‐Hoyos, N., Jürgens, T., Grønborg, M., Kreutzfeldt, M., Schedensack, M., Kuhlmann, T., Schrick, C., Brück, W., Urlaub, H., Simons, M., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22681 · Cited by 107
Tallantyre, E. C., Bo, L., Al-Rawashdeh, O., Owens, T., Polman, C. H., Lowe, J., & Evangelou, N. (2009) · Brain · doi:10.1093/brain/awp106 · Cited by 93
Neurodegeneration Triggers Peripheral Immune Cell Recruitment into the Forebrain
Scheld, M., Rüther, B. J., Große-Veldmann, R., Ohl, K., Tenbrock, K., Dreymüller, D., Fallier-Becker, P., Zendedel, A., Beyer, C., Clarner, T., et al. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.2456-15.2016 · Cited by 82
“Several studies have reported the dissociation between inflammation-driven relapses and clinical progression in MS (Kremenchutzky et al., 2006; Scalfari et al., 2010).”
BackgroundFatigue, depression and progression in multiple sclerosis
Koch, M., Uyttenboogaart, M., van Harten, A., Heerings, M., & De Keyser, J. (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458508088937 · Cited by 59
Early predictors of conversion to secondary progressive multiple sclerosis
Barzegar, M., Najdaghi, S., Afshari-Safavi, A., Nehzat, N., Mirmosayyeb, O., & Shaygannejad, V. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103115 · Cited by 52
MS, MRI, and the 2010 McDonald criteria: A Canadian expert commentary
Selchen, D., Bhan, V., Blevins, G., Devonshire, V., Duquette, P., Grand’Maison, F., Kremenchutzky, M., Lapierre, Y., Li, D., von Riedemann, S. J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318277d144 · Cited by 25
“The natural history is similar to that of PPMS, and some investigators have questioned whether PPMS and progressive relapsing MS are truly separate clinical entities.(3,7)”
BackgroundResultSelf-citation
Metadata
- Authors
- Kremenchutzky, M., Rice, G. P. A., Baskerville, J., Wingerchuk, D. M., & Ebers, G. C.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-01-09
- Volume
- 129
- Issue
- 3
- Pages
- 584-594
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2146853725
- Cited by
- 447
- References
- 54
- FWCI
- 16.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.